Abstract
Engineered foamy virus (FV) vectors have been lauded for their superior safety profiles and stable integration patterns compared to their gammaretroviral counterparts. The drawback has been the belief that FV incorporation is cell cycle-dependent, thereby limiting its utility in post-mitotic tissues such as the central nervous system. In this brief communication, we challenged this theory by examining FV in vivo. We injected equal titers of FV and lentivirus (LV) into the adult rat brain and found that at 1 week, FV transduced a significantly greater volume of bromodeoxyuridine (BrdU)-negative brain parenchyma than did LV. By 8 weeks, however, the volume of transduced tissue was greatly reduced—comparable to LV—and restricted to BrdU+. Taken together, these data implicate a role for FV in short-term gene delivery strategies to the CNS.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Trobridge G, Josephson N, Vassilopoulos G, Mac J, Russell DW . Improved foamy virus vectors with minimal viral sequences. Mol Ther 2002; 6: 321–328.
Hooks JJ, Gibbs Jr CJ . The foamy viruses. Bacteriol Rev 1975; 39: 169–185.
Schweizer M, Turek R, Hahn H, Schliephake A, Netzer KO, Eder G et al. Markers of foamy virus infections in monkeys, apes, and accidentally infected humans: appropriate testing fails to confirm suspected foamy virus prevalence in humans. AIDS Res Hum Retroviruses 1995; 11: 161–170.
Flacone V, Schweizer M, Neumann-Haefelin D . Replication of primate foamy viruses in natural and experimental hosts. Curr Top Microbiol Immunol 2003; 277: 161–180.
Heneine W, Schweizer M, Sandsrtrom P, Folks T . Human infection with foamy viruses. Curr Top Microbiol Immunol 2003; 277: 181–196.
Yu SF, Baldwin DN, Gwynn WR, Yendapalli S, Linial ML . Human foamy virus replication: a pathway distinct from that of retrovirus and hepadnaviruses. Science 1996; 271: 1579–1582.
Saib A, Puvion-Dutilleul F, Schmid M, Peries J, The HD . Nuclear targeting of incoming human foamy virus Gag proteins involves a centriolar step. J Virol 1997; 71: 1155–1161.
Hacein-Bay-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255–256.
Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F . HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002; 110: 521–529.
Wu X, Li Y, Crise B, Burgess SM . Transcription start regions in the human genome are favored targets for MLV integration. Science 2003; 300: 1749–1751.
Trobridge GD, Miller DG, Jacobs MA, Allen JM, Kiem HP, Kaul R et al. Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci USA 2006; 103: 1498–1503.
Josephson NC, Vassilopoulos G, Trobridge GD, Priestley GV, Wood BL, Papayannopoulou T et al. Transduction of human NOD/SCID-repopulating cells with both lymphoid and myeloid potential by foamy virus vectors. Proc Natl Acad Sci USA 2002; 99: 8295–8300.
Liu W, He X, Cao Z, Sheng J, Liu H, Li Z et al. Efficient therapeutic gene expression in cultured rat hippocampal neurons mediated by human foamy virus vectors: a potential for the treatment of neurological diseases. Intervirology 2005; 48: 329–335.
Mergia A, Chari S, Kolson DL, Goodenow MM, Ciccarone T . The efficiency of simian foamy virus vector type-1 (SFV-1) in nondividing cells and in human PBLs. Virology 2001; 280: 243–252.
Kiem HP, Allen J, Trobridge G, Olson E, Keyser K, Peterson L et al. Foamy-virus-mediated gene transfer to canine repopulating cells. Blood 2007; 109: 65–70.
Trobridge G, Russell DW . Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors. J Virol 2004; 78: 2327–2335.
Coleman JE, Huentelman MJ, Kasparov S, Metcalfe BL, Paton JFR, Katovich MJ et al. Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo. Physiol Genomics 2003; 12: 221–228.
Russell DW, Miller AD . Foamy virus vectors. J Virol 1996; 70: 217–222.
Steffens S, Tebbets J, Kramm CM, Lindemann D, Flake A, Sena-Esteves M . Transduction of human glial and neuronal tumor cells with different lentiviral vector pseudotypes. J Neurooncol 2004; 70: 281–288.
Acknowledgements
This research was supported by NIH Grant nos. NS-36674-08 and 30800-14 to RHM.
Author information
Authors and Affiliations
Corresponding author
Additional information
Conflict of interest
The authors state no conflict of interest.
Rights and permissions
About this article
Cite this article
Caprariello, A., Miller, R. & Selkirk, S. Foamy virus as a gene transfer vector to the central nervous system. Gene Ther 16, 448–452 (2009). https://doi.org/10.1038/gt.2008.171
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2008.171
Keywords
This article is cited by
-
Progress and prospects: Foamy virus vectors enter a new age
Gene Therapy (2010)
-
Foamy virus: an available vector for gene transfer in neural cells and other nondividing cells
Journal of NeuroVirology (2010)